# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Q & M Dental Group (Singapore) Limited |
| Establishment Date | January 7, 2008 |
| Headquarters Location | Singapore, Singapore |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | The company has advanced AI-driven dental solutions through its associate EM2AI, which secured medical device licenses in Thailand, Philippines, Vietnam, and Indonesia, enabling commercial deployment across Southeast Asia. EM2AI's technology includes AI-powered automated dental charting using x-rays and intra-oral image analysis, integrated into clinics in Singapore and Malaysia, and licensed for integration into a regional dental solutions provider's platform covering over 1,100 clinics. The Q & M College of Dentistry, accredited with EduTrust Provisional Certification, supports continuous education and AI training for dentists, enhancing clinical practice with AI-Clinical Decision Support Systems. | The Group owns 49% of EM2AI, a company pioneering advanced Artificial Intelligence (AI) in dentistry, deploying AI X-Ray Dental Pathologies Detection, Automated Dental Charting systems, and Dental Health Report accessible via a mobile app. EM2AI is testing the Guided Clinical Decision Support System (GCDSS) in selected outlets to enhance diagnostic speed, accuracy, and ethical treatment planning, minimizing biases in dental care. The Group also utilizes AI solutions such as the AI Guided Clinical Decision Support System (AI-GCDSS) and the cloud-based Integrated Dental Management System (EM2Clinic) to deliver ethical, efficient, and effective patient care, positioning itself as an innovator in patient-centric dental healthcare. |
| Product Advantages | Q & M operates a broad portfolio of dental services across 106 clinics in Singapore and 38 in Malaysia, including premium clinics such as Azure Dental. The company offers a comprehensive range of dental treatments, including aesthetic/cosmetic dentistry, CAD CAM digital dentistry, orthodontics, implant dentistry, and AI-enhanced dental X-rays. The Q & M Dental App facilitates appointment bookings and delivers dental health reports directly to patients, supporting personalized and ethical patient care. | The Group operates the largest network of private dental outlets in Singapore with 106 clinics, including the Q & M Free Dental Clinic providing free dental care to underserved populations. It offers a broad portfolio including dentistry, family medicine, aesthetic services, dental equipment and supplies distribution, and medical laboratory services. The Group also provides postgraduate dental education through the Q & M College of Dentistry, supporting ongoing professional development of its dentists. |
| Brand Recognition | Q & M is positioned as a leading integrated dental healthcare provider in Southeast Asia, with a network expansion strategy including acquisitions and new clinic openings. The company maintains long-term relationships through community initiatives such as the Free Dental Clinic at Chai Chee and partnerships with community organizations. The Q & M College of Dentistry's EduTrust Provisional Certification enhances its reputation as a regional education hub. The company emphasizes ethical practice and patient-centric care aligned with its corporate values. | The Group is recognized as a leading private dental healthcare provider in Asia with a strong regional footprint including operations in Singapore and Malaysia. It has established long-term relationships with community organizations through initiatives such as the Free Dental Clinic and collaborations with social support groups. The Group maintains transparent and regular communication with shareholders and stakeholders, reinforcing its reputation as a responsible corporate citizen committed to ethical business practices and community engagement. |
| Reputation Ratings | The company complies with the Mainboard Rules and Global Reporting Initiative (GRI) Sustainability Reporting Standards, publishing its eighth annual sustainability report for FY2024. It demonstrates commitment to Environmental, Social, and Governance (ESG) principles through initiatives like tree planting aligned with Singapore's green vision, free dental care for underserved populations, and ethical governance practices including a whistle-blowing policy and robust risk management systems. The company maintains transparent stakeholder engagement and adheres to insider trading regulations. | The Company complies with the Mainboard Rules and Global Reporting Initiative (GRI) Sustainability Reporting Standards in its sustainability reporting. It maintains high standards of corporate governance aligned with the Code of Corporate Governance 2018 and the Listing Manual of the Singapore Exchange Securities Trading Limited. The Group engages in comprehensive risk management and internal controls, with independent internal audit reviews and assurance from senior management on the adequacy and effectiveness of these systems as of 31 December 2023. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | To provide dental services in a sustainable manner |
| Vision Statement | To be the leading Dental Healthcare Group in the Region |
| Core Values | Loyalty (忠), Truthfulness (信), Respect (礼), Righteousness (义), Integrity (廉) |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 180,674.0 | 182,723.0 | 181,214.0 | Thousands | SGD |
| Cost of Goods Sold | (20,428.0) | (21,319.0) | (25,170.0) | Thousands | SGD |
| Gross Profit | 160,246.0 | 161,404.0 | 156,044.0 | Thousands | SGD |
| Operating Expense | (136,994.0) | (139,143.0) | (103,612.0) | Thousands | SGD |
| Operating Income | 23,252.0 | 22,261.0 | 52,432.0 | Thousands | SGD |
| Net Profit | 14,637.0 | 11,517.0 | 11,856.0 | Thousands | SGD |
| Income before income taxes | 14,752.0 | 13,664.0 | 14,277.0 | Thousands | SGD |
| Income tax expense(benefit) | (1,686.0) | (2,591.0) | (2,421.0) | Thousands | SGD |
| Interest Expense | (5,372.0) | (5,655.0) | (3,909.0) | Thousands | SGD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 247,773.0 | 258,588.0 | 267,412.0 | Thousands | SGD |
| Current Assets | 84,061.0 | 80,592.0 | 81,803.0 | Thousands | SGD |
| Non-Current Assets | 163,712.0 | 177,996.0 | 185,609.0 | Thousands | SGD |
| Total Liabilities | 139,266.0 | 155,677.0 | 165,164.0 | Thousands | SGD |
| Current Liabilities | 31,810.0 | 33,286.0 | 32,674.0 | Thousands | SGD |
| Non-Current Liabilities | 107,456.0 | 122,391.0 | 132,490.0 | Thousands | SGD |
| Shareholders' Equity | 108,507.0 | 102,911.0 | 102,248.0 | Thousands | SGD |
| Retained Earnings | 33,674.0 | 27,841.0 | 24,163.0 | Thousands | SGD |
| Total Equity and Liabilities | 247,773.0 | 258,588.0 | 267,412.0 | Thousands | SGD |
| Inventories | 10,587.0 | 11,812.0 | 11,091.0 | Thousands | SGD |
| Prepaid Expenses | 1,443.0 | 1,464.0 | 2,144.0 | Thousands | SGD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 40,098.0 | 33,260.0 | 33,550.0 | Thousands | SGD |
| Net Cash Flow from Investing | 6,307.0 | 6,955.0 | (10,995.0) | Thousands | SGD |
| Net Cash Flow from Financing | 33,442.0 | 32,010.0 | (30,468.0) | Thousands | SGD |
| Net Increase/Decrease in Cash | 349.0 | 5,705.0 | (7,913.0) | Thousands | SGD |
| Dividends | 8,804.0 | 7,193.0 | (13,152.0) | Thousands | SGD |


## S2.4: Key Financial Metrics

|       | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Gross Margin | 111.31% | 111.67% | 113.89% |
| Operating Margin | 0.01% | 0.01% | 0.03% |
| Net Profit Margin | 8.10% | 6.30% | 6.54% |
| Current Ratio | 264.26% | 242.12% | 250.36% |
| Quick Ratio | 226.44% | 202.24% | 209.85% |
| Debt-to-Equity | 128.35% | 151.27% | 161.53% |
| Interest Coverage | (0.43%) | (0.39%) | (1.34%) |
| Asset Turnover | 71.36% | 69.48% | N/A |
| Return on Equity | 13.85% | 11.23% | N/A |
| Return on Assets | 5.78% | 4.38% | N/A |
| Effective Tax Rate | (11.43%) | (18.96%) | (16.96%) | 
| Dividend Payout Ratio | 60.15% | 62.46% | (110.93%) |


## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Core dental business: S$173,787,000, Other businesses: S$6,887,000 | Core dental business: S$172,960,000, Other businesses: S$9,763,000 | Primary healthcare: $160,895, Medical laboratory: $11,236, Dental equipment and supplies distribution: $9,083 |
| Revenue by Geographic Region | Singapore: S$167,319,000, Malaysia: S$13,355,000, China: - | Singapore: S$171,438,000, Malaysia: S$11,116,000, China: S$169,000 | Singapore: $167,288, Malaysia: $13,139, China: $787 |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | From 2022 to 2024, Q & M Dental Group's revenue remained relatively stable, with a slight decrease from SGD 181,214 thousand in 2022 to SGD 180,674 thousand in 2024, peaking at SGD 182,723 thousand in 2023. Gross margin showed a marginal decline from 113.89% in 2022 to 111.31% in 2024, indicating a slight reduction in profitability relative to revenue. Revenue by product/service shifted, with the core dental business increasing from SGD 160,895 thousand in 2022 (primary healthcare) to SGD 173,787 thousand in 2024, while other businesses decreased from SGD 20,319 thousand in 2022 (medical laboratory and dental equipment combined) to SGD 6,887 thousand in 2024. Geographically, Singapore remained the dominant market with revenue around SGD 167 million in 2022 and 2024, while Malaysia's contribution was stable around SGD 13 million, and China’s revenue diminished to zero by 2024, indicating a withdrawal or cessation of operations there. |
| Operating Efficiency | Operating margin drastically declined from 0.03% in 2022 to 0.01% in both 2023 and 2024, reflecting a significant drop in operating profitability. Operating income fell sharply from SGD 52,432 thousand in 2022 to SGD 23,252 thousand in 2024, despite stable revenue, indicating increased operating expenses or inefficiencies. Operating expenses rose from SGD 103,612 thousand in 2022 to SGD 136,994 thousand in 2024, suggesting cost management challenges. The ratio of operating income to revenue decreased, highlighting reduced operational efficiency and pressure on profitability despite stable top-line performance. |
| External & One-Off Impact | The effective tax rate improved from (16.96%) in 2022 to (11.43%) in 2024, reducing the tax burden and positively impacting net profit. No explicit non-recurring items or external factors affecting profitability were listed in the provided financial data. The reduction in tax expense contributed to an increase in net profit margin from 6.54% in 2022 to 8.10% in 2024, partially offsetting the decline in operating income. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | N/A | N/A |
| Profitability and earnings quality | N/A | N/A |
| Operational efficiency | N/A | N/A |
| Financial risk identification and early warning | N/A | N/A |
| Future financial performance projection | N/A | N/A |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | N/A | N/A |
| Market Position | N/A | N/A |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | N/A | N/A |
| Operational Risks | N/A | N/A |
| Financial Risks | N/A | N/A |
| Compliance Risks | N/A | N/A |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| N/A | N/A | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | N/A | N/A |
| Control activities | N/A | N/A |
| Monitoring mechanisms | N/A | N/A |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | N/A | N/A |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | N/A | N/A |
| New technologies | N/A | N/A |
| Organisational Restructuring | N/A | N/A |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | N/A | N/A |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | N/A | N/A |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | N/A | N/A |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | N/A | N/A |
